QS Investors’s Novavax NVAX Stock Holding History

QS Investors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$800K	Sell	3,767 -2,300	-38%	-$421K	0.01%	555
2021 Q1	$1.1M	Sell	6,067 -1,655	-21%	-$330K	0.01%	512
2020 Q4	$861K	Buy	7,722 +517	+7%	+$55K	0.01%	554
2020 Q3	$781K	Sell	7,205 -8,995	-56%	-$1.1M	0.01%	528
2020 Q2	$1.35M	Buy	16,200 +1,000	+7%	+$38.2K	0.02%	634
2020 Q1	$207K	Buy	+15,200	New	+$129K	﹤0.01%	1056
2016 Q3	–	Sell	-2	Closed	-$1K	–	1969
2016 Q2	$1K	Buy	+2	New	+$229	﹤0.01%	1718
2016 Q1	–	Sell	-2	Closed	-$1K	–	2033
2015 Q4	$1K	Buy	+2	New	+$308	﹤0.01%	1739

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

QS Investors's NVAX Position: Q2 2021 in Review

QS Investors reduced its Novavax (NVAX) stake by 38% in Q2 2021, selling an estimated $421K and leaving 3,767 shares worth $800K. The position accounts for 0.01% of the portfolio, ranked #555.

QS Investors first reported a position in NVAX in Q4 2015 and has held it in 8 quarters since. The position peaked at $1.35M in Q2 2020. 408 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

QS Investors held 3,767 shares of Novavax worth $800K as of Q2 2021.
QS Investors sold 2,300 Novavax shares in Q2 2021, an estimated $421K.
Novavax made up 0.01% of QS Investors's portfolio in Q2 2021, its #555 holding.
QS Investors first reported a position in Novavax in Q4 2015 and has held it in 8 quarters since.
QS Investors's Novavax position peaked at $1.35M in Q2 2020.
408 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.